好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Completion Rate and Feasibility of Converting AAN Multiple Sclerosis Quality Measures to Digital Measures
Practice, Policy, and Ethics
S12 - Practice, Policy and Ethics (2:36 PM-2:48 PM)
009
To determine the completion rate of the 2020 AAN multiple sclerosis (MS) quality measures (QMs) at a single MS Center and evaluate if they could be collected digitally with discrete data elements in the electronic health record.

There have been attempts to standardize care metrics in MS through QMs but their practical application have yet to be characterized.
In this retrospective cohort study, adult people with MS (PwMS) who had at least 2 visits 24 months ±6 months apart were included. Digital quality measures (dQMs) were created for the 2020 AAN MSQMs and completion rate calculated for the entire sample.  In a 20% random sample, manually abstracted quality measures (mQMs) were also collected through chart review.  The McNemar test was used to determine if there were differences in mQM and dQMs completion rates in this subgroup.

dQMs were calculated for 1,101 PwMS (average age 48 years, 73% female, 65% relapsing course) and a subgroup of 218 PwMS had mQMs collected. Several measures could not be converted to dQMs due to the absence of discrete data elements that could be abstracted from the EHR. The completion rates collected were significantly lower for dQMs compared to mQMs for MRI screening (82% vs 93%, p<0.001), symptom management (8.7% vs 24%, p<0.001), cognitive screening (77% vs 88%, p<0.001), and fatigue management (2.1% vs 32%, p=0.046) while completion rates were similar for fatigue screening (91% vs 89%, p=0.43) and cognitive management (0% vs 5.6%).

The significant differences between manually extracted completion rates and those using digital proxies for multiple care metrics raise concern about the ability to convert many existing AAN QMs into dQMs. Future efforts are needed to develop QMs that leverage EHR data elements allowing for consistent and widespread use in clinical practice that accurately reflect the neurological care that is being delivered.
Authors/Disclosures
Samantha J. Tidd, MD
PRESENTER 		Dr. Tidd has nothing to disclose.
Sarita Walvekar, MD Sarita Walvekar has nothing to disclose.
Saswat Sahoo Mr. Sahoo has nothing to disclose.
Kelly Bowen Kelly Bowen has received personal compensation in the range of $500-$4,999 for serving as a author of a contributed book chapter on an unrelated health care topic with American Medical Association/Elsevier.
Mengke Du (Cleveland Clinic) Mengke Du has nothing to disclose.
Adam Webb, MD, FAAN (Emory University School of Medicine) Dr. Webb has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Spears Rebman Moore, Williams PC.
Marisa P. McGinley, DO (Cleveland Clinic) Dr. McGinley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. McGinley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. The institution of Dr. McGinley has received research support from Biogen. The institution of Dr. McGinley has received research support from Genentech. The institution of Dr. McGinley has received research support from NIH. The institution of Dr. McGinley has received research support from AHRQ. The institution of Dr. McGinley has received research support from EMD Serono.